Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visx

This article was originally published in The Gray Sheet

Executive Summary

Financier Carl Icahn declares intent to nominate Keith Meister to the ophthalmic firm's board of directors. Icahn, who owns 11.6% of the company, had scrapped plans to elect a rival slate of directors in March. A hostile takeover was initially proposed in April 2001 (1"The Gray Sheet" Nov. 26, 2001, p. 30)...

You may also be interested in...



Icahn Renews Effort To Replace Visx Board At Next Shareholder Meeting

Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s

Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.

UsernamePublicRestriction

Register

MT017609

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel